.png)
Actionable Intelligence for
the Future of
Precision Medicine.
EnarroMDx Pharmacogenomics (PGx) testing empowers clinicians with molecular insights to optimize medication selection, reduce adverse reactions, and improve patient adherence through a single non-invasive test.
VISION
Precision Diagnostics for
Clinical Confidence.
Genetic Testing = Better Outcomes
EnarroMDx Pharmacogenomics (PGx) testing empowers clinicians with molecular insights to optimize medication selection, reduce adverse reactions, and improve patient adherence through a single non-invasive test.
MEDICINE FOR REAL LIFE
Diversity drives treatments,precision makes it yours
THERAPUTIC RESPONSE RATES
99%
Population have a variant
58%
Reduction in adverse drug events
By analyzing each patient’s genetic profile, healthcare professionals can predict drug response, minimize adverse effects, and tailor therapies with unprecedented precision. This patient-centered approach not only enhances treatment safety and efficacy but also improves quality of life, making medicine truly personal.
CLINICAL IMPACT
40%
Reduction in trial-and-error
48 %
Likelihood of achieving clinical remission
Non-compliance is a massive hurdle in mental healthcare, usually driven by unbearable side effects like extreme fatigue, rapid weight gain, or brain fog. PGx panels flags these precise risks before a patient ever takes a pill. By cutting adverse reactions nearly in half, patients feel comfortable staying on their treatment plans long-term.
VALUE OF PGX INTEGRATION
57.7%
Market share of oncology applications
40%
Decrease in emergency room visits
By utilizing targeted genetic insights to bypass traditional trial-and-error drug selection, clinicians are driving a significant decrease in emergency room visits for patients treating mood and anxiety disorders—a clinical breakthrough that mirrors a broader systemic shift toward precision medicine, where oncology applications are projected to capture more than half of the global pharmacogenomics market by the end of 2026 due to the critical demand for companion diagnostics.
WHY ENARRO MDX
Where DNA and Medications Meet
EnarroMDx Pharmacogenomics (PGx) testing empowers clinicians with molecular insights to optimize medication selection, reduce adverse reactions, and improve patient adherence through a single non-invasive test. Our clinical reports are designed for immediate clarity. No more deciphering complex genetic nomenclature—just actionable clinical guidance.
COMPANY
Pioneering Clinical Precision in Molecular Diagnostics
50K
Reports Delivered
48h
Average Turnaround
200+
Provider Partners
$100m
Capital
Actionable Intelligence for the Future of Precision Medicine
Navigate complex diagnostic challenges with confidence. Our comprehensive assays deliver rapid, clear, and actionable treatment pathways directly into your clinical workflow.
For Clinicians
Accelerate therapeutic development. Leverage our robust multimedia datasets and AI architecture for biomarker discovery and precise clinical trial matching.
For Life Sciences
Your blueprint. Your health. We demystify genomis testing to help you and your care team make the ost informed, personalized decisions about your treatment.
For Patients
Seamlessly integrate into your existing workflows
Implementing our Precision Health Platform within existing EMR / EHR systems is turnkey. We continually add new partners to keep pace with the needs of our customers.